5-FU	5-Fluorouracil
ACE	angiotensin-converting enzyme
ADCs	Antibody-drug conjugates
ADT	androgen deprivation therapy
AR	androgen receptor
ARBs	angiotensin receptor blockers
ARPIs	androgen receptor pathway inhibitors
ASCVD	Atherosclerotic Cardiovascular Disease
AT1R	angiotensin II type 1 receptor
AUA	American Urological Association
BCG	Bacillus Calmette-Guérin
BEP	Bleomycin, Etoposide, Cisplatin
BP	Blood pressure
CAR	Chimeric Antigen Receptor
CRS	cytokine release syndrome
CSF1R	colony-stimulating factor 1 receptor
CTCAE	Common Terminology Criteria for Adverse Events
CTLA-4	Cytotoxic T-Lymphocyte Antigen 4
CTR-CVT	Cancer therapy-related cardiovascular toxicity
CTR-CD	Cancer therapy-related cardiac dysfunction
EAU	European Association of Urology
ECG	electrocardiography
EP	Etoposide, Cisplatin
ESC	European Society of Cardiology
FAERS	Food and drug administration Adverse Event Reporting System
FDA	Food and drug administration
FGFR	fibroblast growth factor receptor
GC	gemcitabine-cisplatin
GLS	Global longitudinal strain
GnRH	gonadotropin-releasing hormone
HDL	high-density lipoprotein
HER2	human epidermal growth factor receptor 2
HFA-ICOS	Heart Failure Association-International Cardio-Oncology Society
HIF-2α	Hypoxia-inducible factor 2-alpha
HTN	hypertension
ICI	Immune Checkpoint Inhibitor
ICOS	International Cardio-Oncology Society
IHD	Ischemic heart disease
LDL	low-density lipoprotein
LV	Left ventricle
LVEF	Left ventricle ejection fraction
MACE	major adverse cardiovascular events
mCRPC	metastatic castration-resistant prostate cancer
mHSPC	Metastatic hormone-sensitive prostate cancer
MIBC	muscle-invasive bladder cancer
mTOR	Mammalian target of rapamycin
MVAC	methotrexate, vinblastine, doxorubicin, cisplatin
NCCN	National Comprehensive Cancer Network
NO	Nitric oxide
NOX2	NADPH oxidase
NYHA	New York Heart Association
PARP	Poly (ADP-ribose) polymerase
PD-1	Programmed cell death protein 1
PD-L1	Programmed death-ligand 1
PF	Cisplatin, 5-Fluorouracil
PSMA	prostate-specific membrane antigen
RT	Radiotherapy
SCORE2	Systematic Coronary Risk Evaluation 2
SCORE2-OP	Systematic Coronary Risk Evaluation 2—Older Persons
SGLT2	sodium-glucose co-transporter 2
TIP	Paclitaxel, Ifosfamide, Cisplatin
TKIs	Tyrosine kinase inhibitors
TPF	Docetaxel/Paclitaxel, Cisplatin, 5-Fluorouracil
VEGF	vascular endothelial growth factor
VIP	Etoposide/Vinblastine, Ifosfamide, Cisplatin
VTE	venous thromboembolism